Skip to content

Finding the Best Way to Track Vancomycin Levels for MRSA Treatment

Clinical Utility of Trough concentration versus Area Under the Curve/Minimum Inhibitory concentration of Vancomycin for treatment of MRSA infection - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084664
Enrollment
170
Registered
2025-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B956- Staphylococcus aureus as the causeof diseases classified elsewhere

Interventions

Intervention1: AUC/MIC group: The area under the curve / Minimum inhibitory concentration of Vancomycin Dose depends upon the treating physician, sample will be taken after achieving 1 steady state i.

Sponsors

Dr Deepak Kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients microbiologically confirmed with methicillin-resistant staphylococcus aureus infection.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing any kind of renal replacement therapy or having prior Acute Kidney Injury AKI) 2. Patients concerned with meningitis or any central nervous system (CNS) infection 3. Pregnant women

Design outcomes

Primary

MeasureTime frame
Better Clinical Outcomes (Clinical Improvement and laboratory parameters) in trough concentration versus AUC/MIC concentrations of vancomycin 35% discordance between trough and AUCTimepoint: The outcome will be assessed on days 7, 14, and 21, i.e. after 1 week, 2 weeks, and 3 weeks

Secondary

MeasureTime frame
Nephrotoxicity in trough versus AUC/MIC concentration of vancomycin Microbiological cure in trough concentration versus AUC/MIC concentration of vancomycin Timepoint: The outcome will be assessed on days 7, 14, & 21, i.e. after 1 week, 2 weeks, & 3 weeks

Countries

India

Contacts

Public ContactDr Deepak Kumar

All India Institute of Medical Sciences, Jodhpur

deepak1007sharma@gmail.com9116396922

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026